Nadrich & Cohen, LLP

Nadrich & Cohen is investigating Actos (Pioglitazone) victims in all 50 states who’ve been diagnosed with Bladder Cancer. Sadly, this diabetes drug has been linked to Bladder Cancer. On July 11, 2011, the French drug regulatory agency suspended the sale of Actos in France because of the bladder cancer risk . This action was taken after a large study of over 150,000 diabetic patients which compared individuals who used Actos (including the generic version) with those who did not. The study concluded that using a high dose of Actos over a period of one year or more greatly increases the risk of bladder cancer.

Visit Our Website

Unfortunately, Actos is still sold in the United States. In July 2011, the FDA issued a safety alert acknowledging the cancer link but did not restrict the sale of Actos or indicate it planned to withdraw Actos from the market. The purpose of Actos is to maintain correct sugar levels. Its goal is to prevent the liver from producing more sugar than required and allow the efficient use of natural insulin which the liver produces. Previous health warnings prior to bladder cancer included heart failure. As a result of the European supension, the FDA issued a safety alert on June 15, 2011 commenting on the relationship between Actos and bladder cancer. Doctors were told not to prescribe Actos to patients who already have bladder cancer.

Address:
12100 Wilshire Blvd. Suite 1250, 1100 IDS Center
Los Angeles, CA 90025

Phone: (310) 826-8082
Fax: 612-341-0844
Toll Free: (800) 718-4658

Service Areas:
Los Angeles Actos Lawyers, California Actos Lawyers